pay for delay

Refine your results

Filters

Content type

Mission

Displaying 61 - 71 of 71

Press Release

FTC Testifies in Support of Bill Banning Pay-for-Delay Settlements Between Brand and Generic Drug Companies

Date

March 31, 2009

Testifying today on behalf of the Federal Trade Commission before the U.S. House Subcommittee on Commerce, Trade, and Consumer Protection of the Committee on Energy and Commerce, FTC Commissioner J...

Press Release

FTC Sues Drug Companies for Unlawfully Conspiring to Delay the Sale of Generic AndroGel Until 2015

Date

February 2, 2009

The Federal Trade Commission has filed a complaint in federal district court challenging agreements in which Solvay Pharmaceuticals, Inc. paid generic drug makers Watson Pharmaceuticals, Inc. and Par...

Press Release

FTC Testifies Before U.S. Senate on Barriers to Entry of Generic Drugs

Date

May 2, 2007

Testifying today on behalf of the Federal Trade Commission before the U.S. House Subcommittee on Commerce, Trade, and Consumer Protection of the Committee on Energy and Commerce regarding...

Press Release

FTC Provides Senate Testimony on Anticompetitive Patent Settlements in the U.S. Pharmaceutical Industry

Date

January 17, 2007

FTC Study Shows Substantial Increase in Number of Settlements Involving a Payment to the Generic and a Restriction on Generic Entry Testifying today on behalf of the Federal Trade Commission before...

Press Release

FTC Requests Re-Hearing in Schering-Plough Case

Date

April 22, 2005

The Federal Trade Commission today filed a petition with the Court of Appeals for the Eleventh Circuit, in Atlanta, Georgia, requesting that the Court vacate its March 8, 2005 decision in the matter...

Competition Matters

MMA Reports: No tricks or treats—just facts

Date

October 27, 2020

With the passage of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA), Congress required pharmaceutical companies to file certain patent settlement agreements with the...

Competition Matters

Then, now, and down the road: Trends in pharmaceutical patent settlements after FTC v. Actavis

Date

May 28, 2019

Last week, Bureau of Competition staff published a report on filings received in fiscal year (FY) 2016 under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) , the...

Advanced Page

Pay for Delay

Pay-for-Delay: When Drug Companies Agree Not to Compete One of the FTC’s top priorities in recent years has been to oppose a costly legal tactic that more and more branded drug manufacturers have been...

Competition Matters

Quo Vadis Post-Actavis?

Date

March 30, 2016

For more than 15 years, one of the FTC’s top priorities has been to put an end to anticompetitive reverse-payment settlements between brand-name drug makers and their potential generic rivals. In our...

Competition Matters

Antitrust Violation vs. Injury-in-Fact: A distinction that makes a difference

Date

February 26, 2016

There is a basic but important difference between antitrust cases brought by the government and those brought by private parties: All plaintiffs, including government enforcers like the FTC, must...

Competition Matters

Is FTC v. Actavis Causing Pharma Companies to Change Their Behavior?

Date

January 13, 2016

Since 2004, brand-name and generic drug manufacturers have filed certain agreements with the FTC and DOJ as required by the Medicare Prescription Drug, Improvement and Modernization Act (also known as...

Displaying 61 - 71 of 71

Enforcement

Search or browse
the Legal Library

Take action

Competition Matters Blog

New HSR thresholds and filing fees for 2024

Policy

Search or browse
the Legal Library

Take action

Technology Blog

Consumer Facing Applications: A Quote Book from the Tech Summit on AI

Advice and Guidance

Take action

Consumer Advice

Business Guidance

Servicemembers:
Your tool for financial readiness

Get consumer protection basics, plain and simple

Learn how the FTC protects free enterprise and consumers

Looking for competition guidance?

News and Events

Latest News

FTC Sends Refunds to Ring Customers Stemming from 2023 Settlement over Charges the Company Failed to Block Employees and Hackers from Accessing Consumer Videos

Upcoming Event

Informal Hearing on Proposed Trade Regulation Rule on Unfair or Deceptive Fees – April 24, 2024

Follow us on social media

About the FTC

Tag: pay for delay

Refine your results

FTC Testifies in Support of Bill Banning Pay-for-Delay Settlements Between Brand and Generic Drug Companies

FTC Sues Drug Companies for Unlawfully Conspiring to Delay the Sale of Generic AndroGel Until 2015

FTC Testifies Before U.S. Senate on Barriers to Entry of Generic Drugs

FTC Provides Senate Testimony on Anticompetitive Patent Settlements in the U.S. Pharmaceutical Industry

FTC Requests Re-Hearing in Schering-Plough Case

MMA Reports: No tricks or treats—just facts

Then, now, and down the road: Trends in pharmaceutical patent settlements after FTC v. Actavis

Pay for Delay

Quo Vadis Post-Actavis?

Antitrust Violation vs. Injury-in-Fact: A distinction that makes a difference

Is FTC v. Actavis Causing Pharma Companies to Change Their Behavior?

Search or browse the Legal Library

Take action

Competition Matters Blog

Search or browse the Legal Library

Take action

Feature

Vision and Priorities

Technology Blog

Advice and Guidance

Take action

Servicemembers: Your tool for financial readiness

Get consumer protection basics, plain and simple

Learn how the FTC protects free enterprise and consumers

Looking for competition guidance?

Latest News

Upcoming Event

Follow us on social media

Feature

Latest Data Visualization

Featured

Meet the Chair

Tag: pay for delay

Refine your results

Refine your results

Search or browse
the Legal Library

Search or browse
the Legal Library

Servicemembers:
Your tool for financial readiness